The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.20
Bid: 44.10
Ask: 45.90
Change: -0.50 (-1.10%)
Spread: 1.80 (4.082%)
Open: 43.00
High: 43.20
Low: 43.00
Prev. Close: 45.50
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Land-based Broodstock Facility Reaches Milestone

30 Oct 2017 07:00

RNS Number : 9021U
Benchmark Holdings PLC
30 October 2017
 

Benchmark Holdings plc("Benchmark" or the "Company")

 

Construction of land-based salmon broodstock facility reaches significant milestone

 

Benchmark today announces that its new land-based salmon broodstock facility in Norway is now ready to house its first batch of broodstock. The 10,000 square-meter facility will receive delivery of the first stock in November from Salten, the joint venture partner of Benchmark's subsidiary SalmoBreed, who have been growing SalmoBreed's genetic material. Salmon eggs from this stock will be produced early Autumn 2018 and first test batch sales are expected two months later.

 

The new facility will deliver eggs throughout the year for the entire production cycle and will be the first of its kind to do so in Norway. Smolt (young salmon) from SalmoBreed's breeding station in Lønningdal will also be delivered in November. This new site, which is based on Benchmark's Icelandic model, is fully-biosecure and has the capacity to produce over 150 million ova per year.

 

The build of the facility is on schedule and is expected to reach full capacity by Autumn 2019.

 

Malcolm Pye, Benchmark CEO, commented:

"SalmoBreed Salten will be the world's most advanced facility. This additional capacity will allow us to take up our production to meet the increasing demand for disease free, year-round salmon ova and support the strong growth of the Norwegian salmon industry.

 

"Norway is a leading player in salmon and there is a continuous drive towards improvements in production efficiency traits, disease resistance and product quality . Benchmark are well-placed to address this through our robust breeding programmes that are proven to tackle some of the industry's biggest challenges."

 

 

-ENDS-

 

Benchmark Holdings plc

Tel: 020 7920 3150

Malcolm Pye, CEO

Rachel Aninakwah, Communications

Numis

Tel: 020 7260 1000

Michael Meade / Freddie Barnfield (NOMAD)

James Black (Corporate Broking)

Tavistock

Tel: 020 7920 3150

Sophie Praill / Simon Hudson

 

Notes to Editors:

Benchmark challenges the status quo in aquaculture, agriculture and animal healthcare.

 

Since 2000, Benchmark has consistently worked to build a platform to serve its customers, helping farmers to take control of their biological environment through the combination of genetics, nutrition, health and knowledge services. Through its in-depth knowledge of animal biology, Benchmark is able to tackle the key issues in the aquaculture, livestock and companion animal sectors.

 

The Company has proven distribution capabilities in high growth markets and operates internationally with R&D facilities, commercial farms, diagnostic laboratories, manufacturing sites, production facilities and commercial offices across 27 countries in five continents. As at 30 September 2017, Benchmark employed 952 people. 

 

For further information on Benchmark please visit www.benchmarkplc.com 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRABIBDGXDDBGRC
Date   Source Headline
21st Jun 20214:41 pmRNSSecond Price Monitoring Extn
21st Jun 20214:36 pmRNSPrice Monitoring Extension
2nd Jun 20214:41 pmRNSSecond Price Monitoring Extn
2nd Jun 20214:35 pmRNSPrice Monitoring Extension
28th May 20217:00 amRNSTotal Voting Rights
25th May 20217:00 amRNSDirector Dealings
18th May 20217:00 amRNSSecond Quarter and Interim results
30th Apr 20217:00 amRNSTotal Voting Rights
19th Apr 20217:00 amRNSNotice of Q2 and Interim Results
16th Apr 202111:00 amRNSBMK08+CleanTreat Update
31st Mar 20213:41 pmRNSDirector Dealings
31st Mar 20217:00 amRNSTotal Voting Rights
30th Mar 20217:00 amRNSListing of existing senior secured NOK bond
26th Mar 20218:24 amRNSBMK08+CleanTreat Update
19th Mar 20217:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
26th Feb 202110:52 amRNSTotal Voting Rights
22nd Feb 20217:00 amRNSQ1 Results
9th Feb 202112:43 pmRNSResult of AGM
9th Feb 20217:00 amRNSNotice of Q1 Results
29th Jan 20217:00 amRNSTotal Voting Rights
13th Jan 20217:00 amRNSIssue of Equity
8th Jan 20211:13 pmRNSReplacement: DIRECTOR SHARE OPTIONS
8th Jan 20219:57 amRNSDIRECTOR SHARE OPTIONS
6th Jan 20213:45 pmRNSDirector Dealings
31st Dec 20207:00 amRNSTotal Voting Rights
11th Dec 20205:32 pmRNSPosting of Annual Report and Notice of AGM
2nd Dec 20202:09 pmRNSDirector Dealings
1st Dec 20204:02 pmRNSAnnual Financial Report
1st Dec 202011:30 amRNSDirector Dealings
1st Dec 202010:30 amRNSDirector Dealings
1st Dec 202010:21 amRNSPCA Dealing
30th Nov 20207:00 amRNSTotal Voting Rights
27th Nov 20207:00 amRNSQ4 Results
27th Nov 20207:00 amRNSFull Year Results
18th Nov 20207:00 amRNSDirectorate Change
4th Nov 20207:00 amRNSInvestor Presentation for Retail Investors
30th Oct 20207:00 amRNSTotal Voting Rights
27th Oct 20207:00 amRNSNotice of Results
13th Oct 20202:29 pmRNSHolding(s) in Company
12th Oct 20202:50 pmRNSHolding(s) in Company
30th Sep 20207:00 amRNSTotal Voting Rights
29th Sep 20207:00 amRNSHolding(s) in Company
21st Sep 20207:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
11th Sep 20205:58 pmRNSHolding(s) in Company
10th Sep 20209:15 amRNSPositive Opinion from the EMA on BMK08
4th Sep 20207:00 amRNSDirector/PDMR Shareholding
28th Aug 20207:00 amRNSTotal Voting Rights
28th Aug 20207:00 amRNSQ3 Results
21st Aug 20207:00 amRNSNotice of Q3 Results
31st Jul 202011:17 amRNSCompletion of sale of vaccine facility

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.